» Articles » PMID: 34122106

The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions

Abstract

Rheumatoid arthritis (RA) is a debilitating autoimmune disease with grave physical, emotional and socioeconomic consequences. Despite advances in targeted biologic and pharmacologic interventions that have recently come to market, many patients with RA continue to have inadequate response to therapies, or intolerable side effects, with resultant progression of their disease. In this review, we detail multiple biomolecular pathways involved in RA disease pathogenesis to elucidate and highlight pathways that have been therapeutic targets in managing this systemic autoimmune disease. Here we present an up-to-date accounting of both emerging and approved pharmacological treatments for RA, detailing their discovery, mechanisms of action, efficacy, and limitations. Finally, we turn to the emerging fields of bioengineering and cell therapy to illuminate possible future targeted therapeutic options that combine material and biological sciences for localized therapeutic action with the potential to greatly reduce side effects seen in systemically applied treatment modalities.

Citing Articles

Pharmacological modes of plant-derived compounds for targeting inflammation in rheumatoid arthritis: A comprehensive review on immunomodulatory perspective.

Nazakat L, Ali S, Summer M, Nazakat F, Noor S, Riaz A Inflammopharmacology. 2025; .

PMID: 40074996 DOI: 10.1007/s10787-025-01664-7.


Assessing the therapeutic potential of vagus nerve stimulation in autoimmune diseases: A systematic review.

Chan E, Mani A Physiol Rep. 2025; 13(3):e70230.

PMID: 39903575 PMC: 11793006. DOI: 10.14814/phy2.70230.


Unveiling the Anti-Angiogenic Potential of Small-Molecule (Kinase) Inhibitors for Application in Rheumatoid Arthritis.

Khodadust F, Philippon E, Steinz M, van Hamburg J, Van Meerloo J, van Beijnum J Cells. 2025; 14(2).

PMID: 39851530 PMC: 11764070. DOI: 10.3390/cells14020102.


Effect of the Protic vs. Non-Protic Molecular Environment on the to Conformation Change of Phototrexate Drug.

Bencze F, Kiss L, Li H, Yan H, Kollar L, Kunsagi-Mate S Int J Mol Sci. 2024; 25(23).

PMID: 39684413 PMC: 11641236. DOI: 10.3390/ijms252312703.


Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase.

Martinez de la Torre A, Clausen A, Burden A, Weiler S Drug Saf. 2024; 48(2):191-201.

PMID: 39604587 PMC: 11785614. DOI: 10.1007/s40264-024-01490-w.


References
1.
Nelms K, Keegan A, Zamorano J, Ryan J, Paul W . The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999; 17:701-38. DOI: 10.1146/annurev.immunol.17.1.701. View

2.
van Vollenhoven R, Ernestam S, Geborek P, Petersson I, Coster L, Waltbrand E . Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009; 374(9688):459-66. DOI: 10.1016/S0140-6736(09)60944-2. View

3.
Fontana A, Hengartner H, Weber E, Fehr K, Grob P, Cohen G . Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int. 1982; 2(2):49-53. DOI: 10.1007/BF00541245. View

4.
Volin M, Campbell P, Connors M, Woodruff D, Koch A . The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production. Exp Mol Pathol. 2002; 73(2):84-92. DOI: 10.1006/exmp.2002.2460. View

5.
Burger D, Dayer J, Palmer G, Gabay C . Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Pract Res Clin Rheumatol. 2006; 20(5):879-96. DOI: 10.1016/j.berh.2006.06.004. View